25.75
+0.72(+2.88%)
Currency In USD
| Previous Close | 25.03 |
| Open | 25 |
| Day High | 26.46 |
| Day Low | 24.91 |
| 52-Week High | 29.98 |
| 52-Week Low | 13.3 |
| Volume | 1.03M |
| Average Volume | 888,214 |
| Market Cap | 1.53B |
| PE | -14.23 |
| EPS | -1.81 |
| Moving Average 50 Days | 19.44 |
| Moving Average 200 Days | 19.68 |
| Change | 0.72 |
If you invested $1000 in Enliven Therapeutics, Inc. (ELVN) since IPO date, it would be worth $429.17 as of January 14, 2026 at a share price of $25.75. Whereas If you bought $1000 worth of Enliven Therapeutics, Inc. (ELVN) shares 5 years ago, it would be worth $465.14 as of January 14, 2026 at a share price of $25.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
GlobeNewswire Inc.
Sep 28, 2024 1:35 PM GMT
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phas
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
GlobeNewswire Inc.
Sep 18, 2024 8:05 PM GMT
BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inh